CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 444 filers reported holding CRISPR THERAPEUTICS AG in Q1 2022. The put-call ratio across all filers is 0.99 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $12,210 | -27.3% | 269 | -10.0% | 0.00% | -50.0% |
| Q2 2023 | $16,786 | +24.1% | 299 | 0.0% | 0.00% | +100.0% |
| Q1 2023 | $13,524 | +6.0% | 299 | -4.8% | 0.00% | -50.0% |
| Q4 2022 | $12,764 | -52.7% | 314 | -24.2% | 0.00% | -50.0% |
| Q3 2022 | $27,000 | +8.0% | 414 | 0.0% | 0.00% | 0.0% |
| Q2 2022 | $25,000 | -3.8% | 414 | 0.0% | 0.00% | 0.0% |
| Q1 2022 | $26,000 | -18.8% | 414 | -1.9% | 0.00% | -20.0% |
| Q4 2021 | $32,000 | +6.7% | 422 | +55.7% | 0.01% | -16.7% |
| Q3 2021 | $30,000 | +76.5% | 271 | +160.6% | 0.01% | +50.0% |
| Q2 2021 | $17,000 | +30.8% | 104 | 0.0% | 0.00% | 0.0% |
| Q1 2021 | $13,000 | -7.1% | 104 | +16.9% | 0.00% | -20.0% |
| Q4 2020 | $14,000 | +600.0% | 89 | +206.9% | 0.01% | +400.0% |
| Q3 2020 | $2,000 | 0.0% | 29 | 0.0% | 0.00% | 0.0% |
| Q2 2020 | $2,000 | +100.0% | 29 | 0.0% | 0.00% | 0.0% |
| Q1 2020 | $1,000 | – | 29 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 498,558 | $32,581,000 | 55.55% |
| NEA Management Company, LLC | 1,590,002 | $103,907,000 | 5.19% |
| ARK Investment Management | 8,237,122 | $538,296,000 | 3.75% |
| Nikko Asset Management Americas, Inc. | 4,262,736 | $277,078,000 | 3.54% |
| CLOUGH CAPITAL PARTNERS L P | 414,767 | $27,105,000 | 2.89% |
| Integral Health Asset Management, LLC | 220,000 | $14,377,000 | 2.79% |
| PLUSTICK MANAGEMENT LLC | 50,000 | $3,268,000 | 2.48% |
| HC Advisors, LLC | 53,944 | $3,525,000 | 2.43% |
| Green Alpha Advisors, LLC | 27,466 | $1,795,000 | 1.52% |
| EFG Asset Management (North America) Corp. | 84,356 | $5,516,000 | 1.28% |